Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults

  • 23 Accesses

  • 6 Citations

Summary

Twenty-seven adults with refractory or recurrent acute leukaemia were treated with cytosine arabinoside (ara-C) 2 g/m2 infused over 3 h, every 12 h for 6 days, either alone (regimen A) or with vincristine and prednisolone (regimen B). Complete remission was achieved in 9/18 patients (5/12 regimen A, 4/6 regimen B) with acute lymphoblastic leukaemia (ALL), 1/7 patients (1/5 regimen A) with lymphoid blast crisis of chronic myeloid leukaemia (CML.LBC) and 1/2 patients (1/1 regimen B) with acute undifferentiated leukaemia (AUL). A further 5 patients (4 regimen A, 1 regimen B) with ALL, 4 patients (3 regimen A, 1 regimen B) with CML.LBC and 1 patient (regimen A) with AUL showed evidence of significant response. These results confirm the activity of high-dose ara-C in acute non-myelogenous leukaemia and suggest that it might be used with benefit to intensify the initial treatment of ‘poor-risk’ ALL.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Barnett MJ, Richards MA, Ganesan TS, Waxman JH, Smith BF, Butler MG, Rohatiner AZS, Slevin ML, Lister TA (1985) Central nervous system toxicity of high-dose cytosine arabinoside. Semin Oncol 12 (Suppl 3): 227–232

  2. 2.

    Barnett MJ, Greaves MF, Amess JAL, Gregory WM, Rohatiner AZS, Dhaliwal HS, Slevin ML, Biruls R, Malpas JS, Lister TA (1986) Treatment of acute lymphoblastic leukaemia in adults. Br J Haematol 64: 455–468

  3. 3.

    Gottlieb AJ, Weinberg V, Ellison RR, Henderson ES, Terebelo H, Rafla S, Cuttner J, Silver RT, Carey RW, Levy RN, Hutchinson JL, Raich P, Cooper MR, Wiernik P, Anderson JR, Holland JF (1984) Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by Cancer and Leukemia Group B. Blood 64: 267–274

  4. 4.

    Herzig R, Herzig G, Adelstein D, Lazarus H, Phillips G, Wolff S, Hines J, Carter S, Spitzer T (1983) High-dose cytosine arabinoside for the treatment of refractory acute lymphoblastic leukemia in high-risk patients. Clin Res 31: 778A

  5. 5.

    Herzig RH, Phillips GL, Lazarus HM, Wolff SN, Herzig GP (1985a) High-dose cytarabine for the treatment of blastic phase chronic myelogenous leukemia. Cancer Treat Rep 69: 881–883

  6. 6.

    Herzig RH, Lazarus HM, Herzig GP, Coccia PF, Wolff SN (1985b) Central nervous system toxicity with high-dose cytosine arabinoside. Semin Oncol 12 (Suppl 3): 233–236

  7. 7.

    Ho DHW, Frei E (1971) Clinical pharmacology of 1-β-D-arabinofuranosyl cytosine. Clin Pharmacol Ther 12: 944–954

  8. 8.

    Hoelzer D, Thiel E, Löffler H, Bodenstein H, Plaumann L, Büchner T, Urbanitz D, Koch P, Heimpel H, Engelhardt R, Müller U, Wendt F-C, Sodomann H, Rühl H, Herrmann F, Kaboth W, Dietzfelbinger H, Pralle H, Lunscken Ch, Hellriegel K-P, Spors S, Nowrousian RM, Fisher J, Fülle H, Mitrou PS, Pfreundschuh M, Görg C, Emmerich B, Queisser W, Meyer P, Labedzki L, Essers U, König H, Mainzer K, Herrmann R, Messerer D, Zwingers T (1984) Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood 64: 38–47

  9. 9.

    Howard JP, Albo V, Newton WA (1968) Cytosine arabinoside. Results of a cooperative study in acute childhood leukemia. Cancer 21: 341–345

  10. 10.

    Lass JH, Lazarus HM, Reed MD, Herzig RH (1982) Topical corticosteroid therapy for corneal toxicity from systemically administered cytarabine. Am J Ophthalmol 94: 617–621

  11. 11.

    Lazarus HM, Herzig RH, Herzig GP, Phillips GL, Roessmann U, Fishman DJ (1981) Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer 48: 2577–2582

  12. 12.

    Rudnick SA, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, McIntosh S (1979) High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 44: 1189–1193

  13. 13.

    Schauer P, Arlin ZA, Mertelsmann R, Cirrincione C, Friedman A, Gee TS, Dowling M, Kempin S, Straus DJ, Koziner B, McKenzie S, Thaler HT, Dufour P, Little C, Dellaquila C, Ellis S, Clarkson B (1983) Treatment of acute lymphoblastic leukemia in adufts: Results of the L-10 and L-10M protocols. J Clin Oncol 1: 462–470

  14. 14.

    Slevin ML, Rohatiner AZS, Dhaliwal HS, Henry GP, Bell R, Lister TA (1982) A comparison of two schedules of cytosine arabinoside used in combination with adriamycin and 6-thioguanine in the treatment of acute myelogenous leukemia. Med Pediatr Oncol 10 [Suppl 1]: 185–192

  15. 15.

    Slevin ML, Piall EM, Aherne GW, Harvey VJ, Johnston A, Lister TA (1983) Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1: 546–551

  16. 16.

    Wang JJ, Selawry OS, Vietti TJ, Bodey GP (1970) Prolonged infusion of arabinosyl cytosine in childhood leukemia. Cancer 25: 1–6

Download references

Author information

Correspondence to T. Andrew Lister.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Barnett, M.J., Rohatiner, A.Z.S., Ganesan, T.S. et al. A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults. Cancer Chemother. Pharmacol. 19, 169–171 (1987). https://doi.org/10.1007/BF00254573

Download citation

Keywords

  • Cancer Research
  • Prednisolone
  • Complete Remission
  • Cytosine
  • Myeloid Leukaemia